AzTrials
AzTrials

Myocardial InfarctionTIMELYNCT05955625

TIMELY: a Patient-centred Lifestyle Program for Patients With Coronary Artery Disease

A study testing TIMELY in people with Myocardial Infarction and Coronary Artery Disease, run by Tilburg University at 3 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study design: A randomized controlled trial will be used, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group in which patients will receive usual care in combination with the TIMELY intervention for a duration of 6 months. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
TIMELY
Could I receive a placebo?
No, everyone receives an active treatment
How many people
358 participants
Where
3 sitesin 3 countries
Study dates
14 Jul 2023to 7 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 years and over (there is no a priori upper age limit)
  • Documented stable CAD and referred for cardiac rehabilitation (at > 2 weeks but < 10 weeks after PCI or > 4 weeks but <12 weeks after CABG or MI: STEMI or non-STEMI) and/or having documented CAD by coronary angiography (stenosis in a major coronary artery > 50%)
  • Access and ability to operate a smartphone
  • Able to speak the country's native language

Who cannot join

  • Unable to fully understand the provided study information and consequences of participating in the study
  • Presence of a physical impairment interfering with the use of the app or devices (e.g., blindness, wheelchair bound)
  • Known diagnosis of an active malignant tumour (cancer) or any other medical condition associated with a life expectancy of less than one year
  • Unstable cardiovascular, cerebrovascular or other unstable medical condition
  • Refusal to informed consent
  • Having a pacemaker

Trial locations and contacts

3 sites in 3 countries.

3 sites in 3 countries

Germany1 site
  • Klinik Königsfeld

    Ennepetal, Germany, 58256

Other trials in Germany

Netherlands1 site
  • Willem Johan Kop

    Tilburg, North Brabant, 5037 AB

Other trials in Netherlands

Spain1 site
  • Hospital Universitario de Santiago de Compostela

    Santiago de Compostela, A Coruña, 15706

Other trials in Spain

About this study

Official title: TIMELY: A Patient-centred Lifestyle Program to Support the Continuum of Care in Patients With Coronary Artery Disease Using eHealth and Artificial Intelligence

Study design: A randomized controlled trial will be used, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group in which patients will receive usual care in combination with the TIMELY intervention for a duration of 6 months.

Study sample: Female and male patients aged 18 years or over, with documented stable CAD and referred for cardiac rehabilitation (at > 2 weeks but <10 weeks after PCI or >4 weeks but <12 weeks after CABG or MI: STEM or non-STEMI), and/or having documented CAD by coronary angiography (stenosis in a major coronary artery >50%).

Read more

Intervention: Patients randomized to the intervention group will receive the TIMELY app on their phones or tablets for 6 months. Patients will also receive a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviors and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviors during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.

Main study parameters/endpoints: The primary biomedical outcome is a change in the CoroPredict biomarker risk score from baseline (pre-randomization) to completion of the active intervention phase (6 months). The CoroPredict score is an indicator of the 10-year risk of mortality. The primary behavioral outcome is the change from baseline to 6 months in patients' functional status of fitness level (measured using the 6-minute walk test). The study further aims to improve secondary outcome measures: physical activity levels during daily life and cardiovascular responses to exercise, dietary habits, smoking behavior, medication adherence and perceived levels of psychological stress.

Read the detailed description

Background of the study:

Cardiovascular diseases (CVD) are the leading cause of death globally according to the WHO. The highest burden of disease among CVDs is caused by coronary artery disease (CAD). Ageing predisposes patients to a high incidence and prevalence of CAD, in both men and women. Older patients have the greatest mortality and morbidity risk attributable to Chronic Coronary Syndromes (CCS), partially due to the high prevalence of comorbidities. Secondary prevention through comprehensive cardiac rehabilitation (CR) has been recognized as the most cost-effective intervention to limit the physiological and psychological effects of CVDs and reduce the risk of future cardiovascular events.

Contrary to pharmacological or invasive interventions for CAD, CR is far from being well implemented in all European countries and participation rates in available programs range between 30-50% of eligible patients. The TIMELY platform has been developed to stimulate a healthy lifestyle after CR. Patient-related barriers for digital health mainly involve the usability of the CR platform, especially for older patients. Thus, TIMELY includes digital tools and interfaces that will not hinder senior citizens from using them, as patient co-design has guided the development. Since lifestyle changes are key in the prevention and self-management of CAD, the main component of the TIMELY platform will be an app built on behavioral change techniques and models to empower and motivate patients to adopt a healthy lifestyle. Artificial intelligence (AI) will be employed to adapt the platform to the most current needs of the patient. In addition to prevention and self-management, the TIMELY platform will constantly monitor and predict the individual risk for disease progression or serious events and complications using validated risk scores (CoroPredict®). TIMELY will become the first AI-powered, patient-centered eHealth platform that continuously adapts and customizes CR to meet the needs of patients.

Objective of the study:

  1. To investigate whether the TIMELY intervention is superior to usual care in terms of A) reducing the CoroPredict risk score (indicating risk of 10-year mortality: primary biomedical outcome) from baseline to six months; and B) increasing functional fitness levels (6-minute walk test); primary behavioral outcome) from baseline to 6 months

Study design:

A randomized controlled trial study design will be employed, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group, where patients will receive usual care in combination with the TIMELY intervention.

Assessment will take place at 4 time points: baseline, 3, 6 and 12 months post inclusion.

Patients will be asked to fill out questionnaires at 4 timepoints: baseline, 3 months, 6 months and 12 months. Through the TIMELY-platform (app) patients in the intervention group will receive prompts to conduct and ECG and blood pressure measurement. Patient in the intervention group will be wearing a Garmin, which collects information about their physical activity patterns. Lastly, patients will receive physical assessments at three time points (baseline, 6 months and 12 months), namely an exercise test and bloodwork will be done.

Study population:

Patients with documented CAD and who have been referred to cardiac rehabilitation (at > 2 weeks but < 10 weeks after PCI or > 4 weeks but <12 weeks after CABG or MI: STEMI or non-STEMI), and/or have documented CAD by coronary angiography (stenosis in a major coronary artery > 50%) will be included. Recruitment will set special focus on women, recruiting racial/ethnic minorities, older adults, rural residents, and economically disadvantaged individuals.

Intervention:

  1. Timely app: The TIMELY app will help patients adjust their lifestyle in order for them to become healthier. The TIMELY app is supported by artificial intelligence and is based on behavioral change techniques. Through the chatbots the messages aimed at changing the behavior of patients will be personalized. Specific attention will be given to promoting physical activity. Because the chatbots can take the (physical) context of the patient into account, the odds of success are higher.
  2. Wrist-worn activity tracker: Patients will receive an activity tracker, which will collect physical measures, such as level of activity, heart rate and sleep.
  3. Tel-O-Graph: Patients will receive a blood pressure monitor, the Tel-O-Graph. The device additionally measures other hemodynamic parameters through pulse wave analysis (PWA).
  4. Net_ECG: Patients will receive an easy-to-use device capable of registering atrial fibrillation.
  5. eConnect HUB: Patients will receive the eConnect HUB which will transfer all data from the Tel-O-Graph to the researchers.

Patients will complete questionnaires at 4 timepoints: baseline, 3 months, 6 months and 12 months. In addition, patients will have conversations with the chatbots in the app and, based on this, receive encouragement to perform certain behaviors (e.g., exercise more or eat healthier). Through the TIMELY platform (app), patients will receive messages to take their ECG and blood pressure readings. Furthermore, patients will wear a Garmin, which will collect information about their exercise behavior. Finally, at the three measurement moments, patients will receive an exercise test. Blood will also be drawn at these times.

Being tested
TIMELY
Keywords
Percutaneous coronary intervention, Coronary artery bypass graft, Lifestyle behaviour, Physical activity, Lifestyle intervention, Cardiac rehabilitation
Medical subject headings
Myocardial Infarction, Coronary Artery Disease, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TIMELYOther

    The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.

Study groups in NCT05955625
Study groupRoleWhat they receive
TIMELY intervention and care as usualExperimentalThe intervention group will receive the TIMELY intervention including wearable monitoring devices and app in addition to care as usual for a duration of 6 months.
Receives: Other: TIMELY
Care as usualNo interventionThe care as usual group will receive the standard care as they would receive without being enrolled in the current trial.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in risk of mortality

    Risk of mortality will be determined using the validated biomarker risk score CoroPredict, indicating 10-year mortality probability.

    Measured: Baseline and 6 months

  2. Change in functional fitness levels

    Functional fitness levels will be assessed using the 6-minute walking test, using the number of meters walked as the outcome.

    Measured: Baseline and 6 months

Secondary outcomes (7)
  1. Change in physical activity

    Physical activity will be measured by the validated International Physical Activity Questionnaire (IPAQ), a total score of MET minutes can be calculated.

    Measured: Baseline, 3 months and 6 months

  2. Change in cardiovascular exercise tolerance

    Measures of cardiovascular responses to exercise will be based on graded symptom-limited exercise tests, using maximum watt as the outcome

    Measured: Baseline and 6 months

  3. Change in healthy dietary habits

    Dietary habits will be assessed using the dietary questions from the validated Health Promoting Lifestyle Profiles-II questionnaire. Scores range from 9 to 36, with a higher score indicating better dietary habits.

    Measured: Baseline, 3 months and 6 months

  4. Change in weight

    Weight will be measured in kilograms

    Measured: Baseline and 6 months

  5. Change in smoking cessation

    Smoking cessation will be assessed by the validated Fagerström test. Scores range from 0-10 with a higher score indicating higher nicotine dependence.

    Measured: Baseline, 3 months and 6 months

  6. Change in medication adherence

    Medication adherence will be assessed using the validated Medication Adherence Report Scale (MARS-5) questionnaire. Scores range from 5 to 25, with a higher score indicating higher medication adherence.

    Measured: Baseline, 3 months and 6 months

  7. Change in psychological stress levels

    Psychological stress will be measured using validated the Perceived Stress Score questionnaire (PSS-10). Scores range from 0 to 40, with a higher score indicating higher levels of perceived stress.

    Measured: Baseline, 3 months, 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2023
  2. Study start14 Jul 2023
  3. Primary completion7 May 2025
  4. Study completion7 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants are assigned to two groups in parallel for the duration of the study.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
358 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05955625
Sponsor's protocol ID
NL82723.028.23
Acronym
TIMELY
Status last verified
Aug 2025
First submitted
13 Jul 2023
Last updated
27 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: After trial completion, follow-up assessments, and main outcome analysis data will be (partly) available for other researchers.

Publications

  • Habibovic M, Douma E, Schafer H, Sestayo-Fernandez M, Roovers T, Sun X, Schmidt H, Kotewitsch M, Widdershoven J, Cantarero-Prieto D, Mooren F, Pena-Gil C, Gonzalez Juanatey JR, Schmidt M, Malberg H, Tsakanikas V, Fotiadis D, Gatsios D, Bosch J, Kop WJ, Schmitz B. Patient-Centered Risk Prediction, Prevention, and Intervention Platform (TIMELY) to Support the Continuum of Care in Coronary Artery Disease Using eHealth and Artificial Intelligence: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Aug 14;14:e66283. doi: 10.2196/66283.

    PubMed 40812736

Questions about this trial

What is this clinical trial studying?

A study testing TIMELY in people with Myocardial Infarction and Coronary Artery Disease, run by Tilburg University at 3 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Germany, Netherlands, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in risk of mortality (time frame: Baseline and 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05955625, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in